Concurrent daily Cisplatin and high dose radiotherapy in patients with stage III non-small cell lung cancer.

Concurrent chemoradiotherapy (CCRT) including low-dose daily cisplatin (6mg/m2) and high dose radiotherapy (24 fractions of 2,75 Gy to a total dose of 66 Gy) for locally advanced stage III NSCLC resulted in good overall survival (3-year survival rate of 52%(95%CI: 43%-60%) with low toxicity. Prognostic factors for overall survival include GTV lymph nodes and Gender. GTV lymph nodes is the prognostic factor for toxicity. Prognostic factor for distant metastasis is the GTV of the tumor. The incidence of gastrointestinal disorders(grade 3-5) was 11% among which radiation esophagitis grade 3 was 8,4%. The incidence of respiratory, thoracic and mediastinal disorders (grade 3-5) was 8% among which radiation pneumonitis grade 3 was 1,3%.

Source: International Journal of Radiation Oncology * Biology * Physics - July 25, 2018 Category: Radiology Authors: E.M.T. Dieleman, A.L.J. Uitterhoeve, M.W. van Hoek, R.M. van Os, J. Wiersma, M.G.J. Koolen, M.W. Kolff, C.C.E. Koning, J.A. Adam, H.J. Verberne, J.T. Annema, C.R.N. Rasch Source Type: research